A Prospective Natural History Study in Uveal Melanoma

Condition(s) studied

Study summary

The overall objective of this proposal is to develop and utilize a multicenter UM registry that will, in a longitudinal fashion, capture prospective data in order to characterize the natural history of UM and provide data that will be used to support the development of novel therapies for this disease. The care of patients with UM requires a multi-disciplinary team of physicians that commonly requires the involvement of both radiation oncology and interventional radiology, and is typically directed by an ophthalmologic oncologist at time of initial diagnosis of primary disease. Overall management is transitioned to a medical oncologist when distant recurrence is identified. In the case that a patient presents with metastasis at the time of diagnosis, a medical oncologist typically directs overall management. The management of surveillance for the development of metastasis following the treatment of primary disease is variable and, if performed at all, is managed by either an ophthalmologic oncologist or medical oncologist. Thus, the successful development of a registry that aims to capture the data regarding the full natural history of UM requires a collaborative effort including leaders from both the UM ophthalmologic oncology and medical oncology fields. To this end, the investigators have built an initial consortium of key ophthalmologic oncology and medical oncology leaders from multiple major UM centers in the United States.

Eligibility

Primary outcome measure(s)

• Relapse-free Survival Rate — Up to Five years
  Document the relapse-free survival of patients with uveal melanoma from the time of diagnosis of primary disease
• Overall Survival Rate — Up to Five years
  document the overall survival of patients with uveal melanoma from the time of diagnosis of primary disease
• Overall Survival Rate of Patients with Uveal Melanoma — Up to Five years
  document the overall survival of patients with uveal melanoma from the time of development of metastatic disease

Trial sites (17)

More Columbia University trials in Germany

Other trials for the same condition